Premium
Effect of chlorpromazine treatment on monoamine metabolite levels in cerebrospinal fluid of psychotic patients
Author(s) -
WodeHelgodt B.,
Fyrö B.,
Gullberg B.,
Sedvall G.
Publication year - 1977
Publication title -
acta psychiatrica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.849
H-Index - 146
eISSN - 1600-0447
pISSN - 0001-690X
DOI - 10.1111/j.1600-0447.1977.tb06671.x
Subject(s) - homovanillic acid , chlorpromazine , cerebrospinal fluid , metabolite , monoamine neurotransmitter , dopamine , medicine , psychology , endocrinology , serotonin , receptor
Levels of HVA, MOPEG and 5‐HIAA in cerebrospinal fluid (CSF) from psychotic men and women with a schizophrenic symptomatology were measured by mass fragmentography. Measurements were made before, 2 and 4 weeks after treatment with chlorpromazine (CPZ) which was given randomly in doses of 200, 400 or 600 mg per day. Before treatment there were positive correlations between the levels of HVA and 5‐HIAA in both sexes. During CPZ treatment HVA was significantly elevated, whereas MOPEG and 5‐HIAA were reduced. There was a tendency towards tolerance to CPZs effect on HVA during treatment but a significant effect persisted after 4 weeks. No indication of tolerance to the effects on MOPEG or 5‐HIAA was found. There were the same tendencies for the elevations of the HVA/MOPEG and HVN5‐HIAA ratios. The changes in HVA, MOPEG, 5‐HIAA, HVA/MOPEG and HVA/5‐HIAA were related to dose of CPZ in men but not in women. The bidirectional change of the different metabolites in CSF during CPZ treatment excludes a general and non‐specific mechanism for the metabolite changes. The HVA elevations is in accordance with previous results in animals and man, and is pesumably related to blockade of central dopamine receptors. Possible mechanisms for the effects on MOPEG and 5‐HIAA are discussed.